Risk factors and co-morbidities associated with changes in renal function among antiretroviral treatment-naïve adults in South Africa: A chart review.

INTRODUCTION: Our systematic scoping review has demonstrated a research gap in antiretroviral treatment (ART) nephrotoxicity as well as in the long-term outcomes of renal function for patients on ART in South Africa. Bearing in mind the high prevalence of human immunodeficiency virus (HIV) in South Africa, this is of great concern.
OBJECTIVES: To determine the risk factors and co-morbidities associated with changes in renal function in HIV-infected adults in South Africa.
METHODS: We conducted a retrospective study of 350 ART-naïve adult patients attending the King Edward VIII HIV clinic, Durban, South Africa. Data were collected at baseline (pre-ART) and at six, 12, 18 and 24 months on ART. Renal function was assessed in the 24-month period using the Modification of Diet in Renal Disease equation and was categorised into normal renal function (estimated glomerular filtration rate [eGFR] ≥ 60), moderate renal impairment (eGFR 30-59), severe renal impairment (eGFR 15-29) and kidney failure (eGFR < 15 mL/min/1.73 m2). Generalised linear models for binary data were used to model the probability of renal impairment over the five time periods, controlling for repeated measures within participants over time. Risk ratios and 95% confidence intervals (CI) were reported for each time point versus baseline.
RESULTS: The cohort was 64% female, and 99% were Black. The median age was 36 years. At baseline, 10 patients had hypertension (HPT), six had diabetes, 61 were co-infected with tuberculosis (TB) and 157 patients had a high body mass index (BMI) with 25.4% being categorised as overweight and 19.4% as obese. The majority of the patients (59.3%) were normotensive. At baseline, the majority of the patients (90.4%) had normal renal function (95% CI: 86% - 93%), 7.0% (CI: 5% - 10%) had moderate renal impairment, 1.3% (CI: 0% - 3%) had severe renal impairment and 1.3% (CI: 0% - 3%) had renal failure. As BMI increased by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03-1.10) times. The association of HPT with abnormal renal function was found to be insignificant, p > 0.05. The vast majority of patients were initiated on tenofovir disoproxil fumarate (TDF) (90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) or nevirapine (NVP) (43.4%).
CONCLUSION: This study reports a low prevalence of baseline renal impairment in HIV-infected ART-naïve outpatients. An improvement in renal function after the commencement of ART has been demonstrated in this population. However, the long-term outcomes of patients with HIV-related renal disease are not known.

Background

South Africa accounts for approximately 18% of global human immunodeficiency virus (HIV) infections with an estimated prevalence of 6.7 million HIV-infected people.[1] There are almost 1000 new HIV infections, the majority of which are heterosexually transmitted.[2] In an attempt to end the surge of HIV plaguing the African continent, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has established an ambitious but achievable target to have 90% of all people tested for HIV and treated and virologically suppressed by 2020.[3] Providing antiretroviral treatment (ART) to all people living with HIV (PLHIV) irrespective of CD4 count can help prevent HIV-related illness, avert acquired immune deficiency syndrome (AIDS)-related deaths and prevent new HIV infections.[3] South Africa implemented the UNAIDS policy in September 2016.[4] This universal access to ART for PLHIV is likely to lead to an increase in the burden of chronic diseases in South Africa as people are living longer with HIV.[5]

The 2014 study by Stanifer et al. has shown that chronic kidney disease (CKD) has been prevalent and is at an increase in sub-Saharan Africa, with 24% of HIV-infected patients having hypertension (HPT), 18.9% having diabetes and 10% having co-morbid CKD.[6] The use of long-term medication for chronic illnesses can pose a threat to the kidneys, and the use of ART is no exception.[7,8,9] Tenofovir disoproxil fumarate (TDF), a potentially nephrotoxic drug,[10,11] is widely used as first-line ART in South Africa, and screening for baseline renal dysfunction prior to TDF initiation is essential.[12] The South African ART guidelines recommend a serum creatinine and creatinine clearance at baseline (prior to ART initiation) and then at three months, six months and annually thereafter for patients on TDF.[13]

Our systematic scoping review has demonstrated a research gap in ART nephrotoxicity, particularly with TDF, as well as the long-term outcomes of renal function for patients on ART in South Africa. This is of great concern because we do not know the burden of ART nephrotoxicity or morbidity that our population may experience. Further, with the current health infrastructure, access to nephrologists and dedicated renal services are limited to a few tertiary hospitals. In this study, we aim to determine the risk factors and co-morbidities associated with changes in renal function in HIV-infected adults in South Africa. We anticipate that the results of this study will pave the way for prospective studies regarding the morbidity and mortality of ART nephrotoxicity and influence the expansion of renal services offered in the public health sector.

Methodology

Design

We conducted a retrospective study of 350 ART-naïve adult patients (18 years and older) attending the King Edward VIII HIV clinic, Durban, South Africa.

Study population

Our study population was ART-naïve, HIV-infected adult patients who presented to us from across KwaZulu-Natal seeking initiation on ART. We included patients who were initiated on ART from April 2010 to December 2013 and followed up over a 24-month period. Patients already on ART who were transferred to the clinic were excluded.

Data extraction

Clinical data were extracted from medical records of patients attending the HIV clinic at King Edward VIII Hospital in the study period from April 2010 to December 2013. Data were collected at baseline (pre-ART) and at six, 12, 18 and 24 months on ART. Data collected included socio-demographics, clinical parameters (weight, height, body mass index [BMI], blood pressure [BP], pulse, finger prick glucose and urine dipstick analysis), history of co-morbidities (HPT, diabetes, tuberculosis [TB] and pregnancy), laboratory data (serum creatinine and estimated glomerular filtration rate [eGFR]) and the type of ART regimen. We also documented patients who were lost to follow-up.

Outcome measures

Chronic kidney disease was defined as either kidney damage or a GFR < 60 mL/min/1.73 m2 for ≥ three months irrespective of cause.[14] Estimated GFR (eGFR) used in data analyses was calculated using the simplified Modification of Diet in Renal Disease (MDRD) equation without the ethnicity factor: eGFR (mL/min/1.73 m2) = 175 × [Scr(µmol/L)/88.4]−1.154 × Age (years)−0.203 × (0.742, if female)[15] and was performed at the National Health Laboratory Services (NHLS) at King Edward VIII Hospital. The formula was adjusted to correct for the use of µmol/L as the unit of measure for serum creatinine.[15] For this study, we modified the staging of CKD from that of the Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (Table 1)[14] because the NHLS reports creatinine clearance above 60 µmol/L as > 60 µmol/L and does not specify the actual eGFR level. For those patients who did not have a documented eGFR from the lab because either the age or gender was not documented on the lab request form, we manually calculated the value using the MDRD equation above, with age and gender captured during data collection. Proteinuria detected on urine dipstick analysis refers to the presence of protein in the urine.

TABLE 1

Staging of chronic kidney disease.

Description†	eGFR mL/min/1.73 m2
Normal renal function	≥ 60
Moderate renal impairment	30–59
Severe renal impairment	15–29
Kidney failure	< 15 (needs dialysis)

eGFR, estimated glomerular filtration rate.

, An adaptation of the CKD classification of the KDOQI of National Kidney Foundation.

As per the South African Hypertension Guidelines, HPT is defined as a persistent elevation of BP ≥ 140/90 mmHg.[16] The classification of HPT into four categories was made in accordance with the JNC8 guidelines (Table 2).[17] Body mass index (BMI) is an index of weight-for-height that is used to classify persons as underweight, normal, overweight or obese. Body mass index is calculated as weight (kilograms)/height (metres)². Classification of BMI was based on that of the World Health Organization (WHO) Global Database on BMI (Table 3).[18]

TABLE 2

Classification of hypertension.

Classification†	Systolic blood pressure (mmHg)‡	-	Diastolic blood pressure (mmHg)
Normal	< 120	AND	< 80
Pre-hypertension	120–139	OR	80–89
Stage 1	140–159	OR	90–99
Stage 2	≥ 160	OR	≥ 100

Source: Hypertension: The Silent Killer: Updated JNC-8 Guideline Recommendations. Alabama Pharmacy Association, Montgomery, AL, USA; 2015.[17]

, Classification as per JNC8 guidelines;

, BP should be categorised according to the highest level of BP whether systolic or diastolic.

TABLE 3

Classification of body mass index.

Classification†	BMI‡ kg/m2
Underweight	< 18.50
Normal range	18.50–24.99
Overweight	≥ 25.00
Obese	≥ 30.00

BMI, body mass index.

, Classification as per WHO guidelines;

, BMI = weight (kilograms)/height (metres)2.

Statistical analysis

IBM SPSS version 24 and Stata version 13 were used for data analysis. To assess the effect of time on ordinal outcomes, the outcomes were first categorised into binary variables indicating the presence or absence of a condition. eGFR categories were collapsed into normal (eGFR ≥ 60 mL/min/1.73 m2) versus renal impairment (moderate to kidney failure, eGFR < 60 mL/min/1.73 m2). Blood pressure categories were dichotomised to normal versus HPT – the latter included pre-hypertension. Generalised linear models for binary data were used to model the probability of renal impairment over the five time periods, controlling for repeated measures within participants over time. Risk ratios and 95% confidence intervals (CI) were reported for each time point versus baseline. A p-value of < 0.05 represented statistical significance.

Ethical consideration

Ethical approval was obtained from the KwaZulu-Natal Department of Health and from the University of KwaZulu-Natal (UKZN) Biomedical Research and Ethics Council (BREC) Ethics Committee. Full ethical approval was obtained from the BREC, and permission to conduct the research was granted by King Edward VIII Hospital management. All data generated or analysed during this study are included in this published article and its supplementary information files.

Results

Demographics

The baseline characteristics of the 350 patients included in the analysis are illustrated in Table 4. Their mean age was 36.9 years, with a standard deviation of 9.7 years. The range was from 18 to 72 years, with a median age of 36 years. The cohort was 64% female, and 99% were Black. Of the women, 16% were pregnant at baseline. Also at baseline, 10 patients had HPT, six had diabetes, 14 had a combination of HPT and diabetes mellitus and 61 were co-infected with TB. At baseline, 157 patients had a high BMI, with 25.4% being categorised as overweight and 19.4% as obese (Figure 1). Because of a lack of documentation of either the weight or height or both, 20 patients did not have their BMI documented at baseline. The mean CD4 count at baseline was 177 cells/μL, with a standard deviation of 161.9 cells/μL. The majority of the patients (59.3%) were normotensive, while 24.1% were classified as pre-HPT, 9.9% as Stage 1 HPT and 6.7% as Stage 2 HPT (Figure 2).

TABLE 4

Baseline demographics of the 350 patients included in the analyses.

Variable	Category	n	%	95% CI
Gender	Female	224	64	0.59–0.69
	Male	126	36	0.31–0.41
Race	Black	348	99.4	0.98–1.00
	Indian	0	0	0.0
	White	0	0	0.0
	Mixed race	2	0.6	0.00–0.02
HPT	No	340	97.1	0.95–0.98
	Yes	10	2.9	0.02–0.05
Diabetes mellitus	No	344	98.3	0.96–0.99
	Yes	6	1.7	0.01–0.04
HPT and diabetes mellitus	Yes	14	0.6	0.001–0.02
TB	No	288	82.5	0.78–0.86
	Yes	61	17.5	0.14–0.22
Pregnant (women)	No	188	83.9	0.86–0.93
	Yes	36	16.1	0.07–0.14

CI, confidence intervals; HPT, hypertension; TB, tuberculosis.

FIGURE 1

Body mass index categories of 350 patients at baseline.

FIGURE 2

Hypertension categories of 350 patients at baseline.

Baseline renal function

At baseline, the majority of the patients (90.4%) had a normal renal function (95% CI: 86% – 93%), 7.0% (CI: 5% – 10%) had moderate renal impairment, 1.3% (CI: 0% – 3%) had severe renal impairment and 1.3% (CI: 0% – 3%) had kidney failure (Table 5). The eGFR for 49 patients was not documented at baseline. Relative to baseline, the risk of developing renal failure decreased at the subsequent time points (Appendix 1). At six months, the risk of developing renal failure was 82% (CI: 5% – 72%) lower than baseline, at 12 months it was 56% (CI: 22% – 87%) lower, at 18 months it was 72% (CI: 10% – 77%) lower and at 24 months the risk was 49% (CI: 29% – 91%) lower than baseline.

TABLE 5

Categories of renal impairment from baseline to 24 months on antiretroviral treatment.

eGFR categories (eGFR mL/min/1.73 m2)	Baseline			6 months			12 months			18 months			24 months
	n	%	CI	n	%	CI	n	%	CI	n	%	CI	n	%	CI
Normal (eGFR > 60)	272	90.4	0.86–0.93	112	98.2	0.93–1.00	181	95.8	0.92–0.98	143	97.3	0.93–0.99	212	95.1	0.91–0.97
Moderate RI (eGFR 30–59)	21	7.0	0.05–0.10	1	0.9	0.00–0.06	6	3.2	0.01–0.07	2	1.4	0.00–0.05	9	4.0	0.02–0.08
Severe RI (eGFR 15–29)	4	1.3	0.00–0.03	0	0.0	0	1	0.5	0.00–0.04	0	0.0	0	1	0.4	0.00–0.03
Kidney failure (eGFR < 15)	4	1.3	0.00–0.03	1	0.9	0.00–0.06	1	0.5	0.00–0.04	2	1.4	0.00–0.05	1	0.4	0.00–0.03
Total	301	-	-	114	-	-	189	-	-	147	-	-	223	-	-

eGFR, estimated glomerular filtration rate; CI, confidence interval, RI, renal impairment

Appendix 2 demonstrates the characteristics of the 29 patients with baseline renal impairment and depicts the trend of the eGFR over various time points. Of those patients with abnormal renal impairment at baseline, females predominated with renal impairment at 79%. Twenty-four per cent were co-infected with TB, while one patient had HPT. The average age of the 29 patients was 45 years. The median CD4 at baseline of these 29 patients was 147 cells/μL. Seven patients of the 29 patients (24%) with baseline renal impairment had persistent renal impairment at 24 months. Eight of the 29 patients did not have an eGFR done at 24 months. One patient was lost to follow-up at 24 months. The eGFR of 13 patients (44.8%) normalised at 24 months.

In 2010, fixed-dose combinations were unavailable in the public sector; therefore, patients were initiated on individual antiretroviral agents. The vast majority of patients were initiated on TDF (90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) or nevirapine (NVP) (43.4%). Twenty-three of the 29 patients with baseline renal impairment (eGFR < 60 mL/min/1.73 m2) were commenced on a TDF-based regimen. Of the 10 patients with a baseline eGFR < 50 mL/min/1.73 m2 who were commenced on TDF, 7 had a normalisation of eGFR by 24 months, while three experienced deterioration in renal function. Two of the patients had TDF discontinued at 18 months and replaced with abacavir (ABC). The remaining patients with renal impairment were either initiated on ABC (three patients), zidovudine (AZT) (two patients) or stavudine (d4T) (one patient). Fourteen of the 36 pregnant women were initiated on AZT, while the remaining 22 were initiated on TDF. The remaining patients were initiated on either d4T, AZT or ABC by the attending clinician as first-line treatment with no reason specified. Figure 3 demonstrates this distribution of ART at baseline.

FIGURE 3

Distribution of antiretroviral treatment at treatment initiation.

Risk factors associated with abnormal renal function

The factors tested for association with abnormal renal function were age group, time, BMI and HPT. The factors which remained significant in the model are shown in Appendix 3. Compared with those aged under 30 years, there was no significant difference in renal impairment in those aged 30–49 years, p = 0.128 (CI: 2.51–1.52), while those aged ≥ 50 years were 6.8 (CI: 1.90–24.54) times more likely to develop renal impairment, p = 0.003. Time still remained a significant predictor. As time increased, the risk of abnormal renal function decreased. As BMI increased by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03–1.10) times. A CD4 threshold of < 200 cells/μL had no significance to the association of impaired renal function, p = 0.378. The association of HPT with abnormal renal function was found to be insignificant over time, p = 0.194. Patients with HPT and aged ≥ 40 years in comparison with those with HPT and aged < 40 years did not show any significant risk for renal impairment, p = 0.226. Similarly, patients with HPT and a CD4 < 200 cells/μL did not have a significant risk for renal impairment compared with those patients with HPT and a CD4 ≥ 200 cells/μL, p = 0.384. A total of 21 patients (6%) were lost to follow-up over the two years, and 94% were retained in care.

Urine dipstick analysis

Only five patients in the entire cohort had urine dipsticks performed at various time points (three at baseline, one at six months and one at 12 months). The test strip was positive for proteinuria in four of the five patients (80%), and three of these four patients (75%) with proteinuria were on a TDF-based regimen with a normal eGFR. The remaining patient had renal impairment and was on an ABC regimen.

Discussion

We aimed to determine the risk factors and co-morbidities associated with changes in renal function in an adult cohort with HIV in South Africa. The cohort was mainly female and a large proportion of patients were either pregnant or co-infected with TB. The prevalence of renal impairment at baseline was found to be relatively low. Females predominated with baseline renal impairment and the majority of the patients were co-infected with TB. Of those patients with baseline renal impairment, the majority had a normalisation of their eGFR by 24 months. The risk of developing renal impairment decreased over the two-year period while patients were on ART. Risk factors found to be significant for renal impairment were older age, p = 0.003, and an increase in BMI, p < 0.001. In this cohort, HPT did not impact renal impairment significantly, p = 0.194, nor did a CD4 < 200 cells/μL, p = 0.378. Tenofovir disoproxil fumarate was the ART of choice for ART initiation along with 3TC and either NVP or EFV in keeping with South African National ART guidelines.[13] Surprisingly, one-third of the patients with baseline renal impairment were initiated on a TDF-based regimen in contravention of the standard ART guidelines. These guidelines state that TDF should not be initiated in patients with an eGFR of < 50 mL/min/1.73 m2. This probably reflects the practice in clinics that may be understaffed where there may be a tendency for errors to occur.

Similar studies conducted in South Africa showed a low prevalence of baseline renal impairment in an HIV-infected cohort[12,19,20] and some showed an improvement in eGFR after starting ART.[19,21,22] Similar findings were noted in an African study by Stohr et al.[23] carried out in Mozambique and Zimbabwe. As HIV has been shown to have a direct renal pathogenic role,[24,25] we can deduce that treating the disease with ART diminishes the renal pathogenic effect. However, there is a lack of information on the long-term outcomes of renal disease in HIV-infected patients. Not all our patients experienced a resolution in their renal function as described earlier. Our cohort comprised mainly Black patients and therefore we were unable to compare the renal function of different ethnicities. Consensus regarding gender as a risk factor for renal dysfunction could not be arrived at, as some studies found women to be at greater risk,[19,26] while others found men to be at greater risk.[20] Older age has been documented in numerous studies including ours as a risk factor for renal impairment.[19,20,27] A low CD4 count, high viral load and low haemoglobin are other variables found to be associated with a lower eGFR.[12,19,20,27] In our study, despite having a mean CD4 of 177 cells/μL, a CD4 threshold of < 200 cells/μL was insignificant as a risk factor for renal impairment. Majority of the cohort had a baseline CD4 < 200 cells/μL in keeping with the National ART guidelines at the time (CD4 < 200 qualified for ART initiation).[13] We did not assess a high viral load and low haemoglobin as variables in our study.

A high BMI has been documented in international literature as a modest risk factor for renal impairment over time.[27] To the best of our knowledge, this is the first South African study to demonstrate BMI as a risk factor associated with changes in renal function in an HIV-infected cohort. This is a significant finding as a high BMI is also a risk factor for other chronic diseases such as HPT, diabetes and cardiovascular disease,[28,29] which in turn are risk factors for CKD.[6]Although we did not find a significant link between HPT and renal impairment, this has been observed in other studies.[26,27] A possible explanation for our findings could be the duration for which we collected data (two years) and ethnicity (our cohort mainly comprised Black patients), while in the other studies the duration was 96 weeks and 31 months, respectively, in predominantly White cohorts.[26,27]

Several studies have described TDF-associated nephrotoxicity as a pattern of renal injury involving the proximal renal tubule sometimes with Fanconi syndrome occurring together with decreased renal function.[7,30] They recommend monitoring of renal function to prevent these outcomes.[10,30,31] The South African ART guidelines recommend monitoring of renal function with urine dipsticks, a serum creatinine and eGFR levels at baseline, six months, 12 months and annually thereafter for patients on TDF.[13,32] The rate of adherence to these guidelines is not known. In our study, we found missing serum creatinine and eGFR levels at six months, 12 months and 24 months. A possible explanation for this is that clinicians were attending to large clinic numbers with a poorly kept paper filing system, wherein these routine checks were missed. In addition, clinicians were missing the 12-month serum testing because they calculated the timing of this test as one year from the six-month blood test, which resulted in the test being taken at 18 months. Of those patients initiated on TDF with an eGFR < 50 mL/min/1.73 m2, only a few patients had deterioration in renal function, resulting in the discontinuation of TDF. Most likely this is because the majority had a reversible cause for the renal impairment, for example, dehydration rather than actual renal disease.

Urine analysis is important to detect proximal renal tubular damage in patients on TDF as well as undiagnosed HIV-associated nephropathy (HIVAN), yet they were rarely performed in our clinic setting, again, possibly because of large volumes of clinic patients combined with staff shortages and limited ablution facilities. Fabian et al.[33] showed that urinary abnormalities were common in HIV-infected, ART-naïve outpatients and recommended that routine urinary screening of all new patients at ART clinics should be practiced. However, urine dipstick usage as a solitary screening tool is a topic with much debate, as research both locally and internationally suggests their poor validity in detecting proteinuria.[20,34]

A study conducted in South Africa by Han et al.[35] showed that microalbuminuria alone could be an early marker for HIVAN. HIV-associated nephropathy is the most common histology seen on renal biopsy in South African patients.[21,22] It is commonly found in Black patients who seem to have a genetic predisposition for the disease[36] and Kasembeli et al.[37] documented this finding in a South African cohort. Therefore, by deferring urine analysis, we may be missing an opportunity to detect early HIVAN in our predominantly Black high-risk cohort. The best method for urine screening is not known.[6] Relying solely on serum creatinine levels and eGFR is inappropriate for this group of patients as HIVAN can occur with a normal renal function.[35]

It is important to highlight that when boosted with ritonavir or cobicistat, the renal toxicity profile of tenofovir tends to be worse.[30,38] In this study, the majority of patients were treated with TDF, 3TC and either EFV or NVP, which tends to have a more favourable renal toxicity profile.[30,38]

A strength of this study we feel is that we had a good sample size of 350 and a good representation of the profile of patients who are currently attending ART clinics across South Africa. The main limitation of the study would be that of missing data, for example, the weight, height, BP and baseline serum creatinine were not documented in some patients. Lastly, we cannot comment on the diagnosis of those with persistent renal impairment at 24 months as renal biopsies were not done.

Conclusion

This study shows a low prevalence of baseline renal impairment among HIV-infected, ART-naïve outpatients and an improvement in renal function after the commencement of ART. This highlights the possibility of HIV being the likely cause of the renal impairment at baseline. Caution should be exercised when excluding TDF as an option at initiation owing to renal impairment, as most patients have a reversible cause for the renal dysfunction which can be corrected before ART initiation. Ultimately, TDF as part of a fixed-dose combination is a once daily dose which greatly improves adherence. Long-term outcomes of patients with HIV-related renal disease are not known. Body mass index has been associated with the development of renal impairment in an HIV-infected cohort. With the recently introduced universal access to ART in South Africa, we anticipate the affliction of chronic diseases and their complications including renal disease to increase. Therefore, prospective studies targeting patients with HIV-related renal disease are needed in South Africa. Research on the most cost-effective and accurate urine diagnostics is also needed to detect early renal disease. Urine microalbumin screening is not routinely practiced at ART clinics despite being found to be an early marker for HIVAN.[35] We need to improve and reinforce optimal primary care in our clinics, including regular BP monitoring, anthropometry and urine analysis. Lastly, we need to explore the influence of a high BMI in our HIV-infected patients and its link to CKD and other chronic diseases in order to promote a healthy lifestyle and dietician services as part of a holistic management of our patients (an area often neglected in clinical practice).

TABLE 1-A2

Follow-up of estimated glomerular filtration rate of the 29 patients with baseline renal impairment.

Patient	Variable	Baseline	6 months	12 months	18 months	24 months
49/1172 years	eGFRCD4	54.79159	NdNd	> 6075.04178	NdNd	Nd182
FemaleBMI 27.1	ART	TDF,3TC,EFV
205/1153 years	eGFRCD4	56.81147	> 6078.51213	> 6069.05259	> 6060.68312	> 6060.68356
FemaleBMI 28.7	ART	TDF,3TC,EFV
568/1051 years	eGFRCD4	49.002.00	NdNd	NdNd	NdNd	> 6086.41233
FemaleBMI nd	ART	TDF,3TC,EFV
275/1132 years	eGFRCD4	50.46109	NdNd	NdNd	> 60124.02345	NdNd
FemaleBMI 28.1	ART	TDF,3TC,EFV
371/1136 years	eGFRCD4	59.4217	NdNd	> 60105.4541	> 60108.8831	NdNd
Male, TBBMI nd	ART	TDF,3TC,EFV
567/1159 years	eGFRCD4	46.13143	NdNd	NdNd	> 6063.40146	40.61161
MaleBMI 21.3	ART	TDF,3TC,EFV
578/1151 years	eGFRCD4	58.00147	NdNd	47.40416	NdNd	44.95539
Female, TB34.60	ART	TDF,3TC,EFV
587/1156 years	eGFRCD4	38.45227	NdNd	> 6078.97363	NdNd	> 6072.68436
FemaleBMI 46.5	ART	TDF,3TC,EFV
788/1140 years	eGFRCD4	51.65236	NdNd	NdNd	> 60154.4850	NdNd
MaleBMI 27	ART	TDF,3TC,EFV
1033/1160 years	eGFRCD4	47.95324	NdNd	> 6090.18692	NdNd	NdNd
FemaleBMI 37.8	ART	TDF,3TC,EFV
1111/1136 yearsFemale	eGFRCD4	52.59277	> 6086.38634	> 6082.12424	> 6070.40413	> 6068.42447
BMI 26.4	ART	TDF,3TC,NVP	TDF,3TC,EFV
1145/1150 years	eGFRCD4	57.81365	NdNd	> 6063.45438	> 6062.11518	> 6072.79516
MaleBMI 20.7	ART	TDF,3TC,EFV
819/1033 years	eGFRCD4	3.6813	4.01Nd	NdNd	LTFULTFU	LTFULTFU
Male, HPTBMI 22.5	ART	ABC,3TC,EFV
51/1246 years	eGFRCD4	20.63238	59.23431	11.88362	34.26187	34.83370
FemaleBMI 46.1	ART	TDF,3TC,EFV			ABC,3TC,EFV
150/1242 years	eGFRCD4	53.9816	NdNd	> 6073.5049	> 6079.5978	NdNd
FemaleBMI 27.0	ART	TDF,3TC,NVP			AZT,3TC,Aluvia
341/1251 years	eGFRCD4	14.1746	NdNd	NdNd	LTFULTFU	15.78227
MaleBMI 32.3	ART	AZT,3TC,EFV	ABC,3TC,EFV
346/1249 years	eGFRCD4	25.33128	NdNd	54.25287	NdNd	43,82331
Male, TBBMI 25.1	ART	ABC,3TC,EFV
416/1246 years	eGFRCD4	51.18150	NdNd	> 6071.06418	NdNd	> 6080.80393
FemaleBMI 45.6	ART	TDF,3TC,EFV				FDC
475/1230 years	eGFRCD4	37.9820	NdNd	> 6083.84330	NdNd	> 60117.48410
Female, TBBMI 14.6	ART	TDF,3TC,EFV			FDC
843/1242 years	eGFRCD4	58.80284	NdNd	> 6061.12475	NdNd	58.07591
FemaleBMI 38.1	ART	TDF,3TC,EFV		FDC
431/1269 years	eGFRCD4	19.82139	> 6077.02328	NdNd	> 6071.96519	> 6073.17700
Female, TBBMI 52.8	ART	ABC,3TC,EFV
476/1230 years	eGFRCD4	14.4945	NdNd	> 6083.84330	NdNd	> 60101.81410
FemaleBMI 14.6	ART	TDF,3TC,EFV
600/1244 years	eGFRCD4	49.38299	Nd299	> 60106.38527	NdNd	> 6085.89637
FemaleBMI 42.5	ART	TDF,3TC,EFV				FDC
1039/1040 years	eGFRCD4	39.70193	NdNd	NdNd	> 6069.91600	> 6076.59566
FemaleBMI 24.8	ART	AZT,3TC,NVP
1266/1049 years	eGFRCD4	24.22218	Nd287	24.82367	NdNd	NdNd
Female, TBBMI 37.4	ART	TDF,3TC,EFV			ABC,3TC,EFV
1273/1047 years	eGFRCD4	51.55190	LTFULTFU	LTFULFTU	LTFULFTU	Nd191
FemaleBMI 47.5	ART	TDF,3TC,EFV
494/1026 years	eGFRCD4	50.4836	NdNd	> 60100.92246	NdNd	> 6077.43198
FemaleBMI 22.8	ART	D4T,3TC,EFV		D4T,3TC,NVP
1336/1049 years	eGFRCD4	56.99163	NdNd	> 6099.80222	NdNd	6.90298
FemaleBMI 21.3	ART	TDF,3TC,EFV
1339/1025 years	eGFRCD4	46.2471	> 60110.06Nd	NdNd	NdNd	> 60125.36299
Male, TBBMI 19.4	ART	TDF,3TC,EFV

Nd, not done; ART, antiretroviral treatment; TB, tuberculosis; BMI, body mass index; LTFU, lost to follow-up; FDC, fixed-dose combination.